As an E3 ubiquitin ligase, only two experimentally validated substrates of RNF149 were reported so far: wild-type but not mutant BRAF in colorectal cancer [10], and EPHA2 in NPC [11]. This evidence concerns the gene BRAF and nasopharyngeal carcinoma.